A participant in the company’s late-stage coronavirus vaccine trial reportedly developed severe neurological symptoms. Now experts must assess whether the vaccine was responsible.
Tag: your-feed-healthcare
Russians Publish Early Coronavirus Vaccine Results
The first batch of public data from the “Sputnik V” vaccine showed that it was safe and produced an immune response. No one knows yet whether it prevents coronavirus infections.
DIY Coronavirus Vaccines? These Scientists Are Giving Themselves Their Own
Impatient for a coronavirus vaccine, dozens of scientists around the world are giving themselves — and sometimes, friends and family — their own unproven versions.
You Probably Won’t Catch the Coronavirus From Frozen Food
Reports that the virus was detected in a trans-continental shipment of frozen chicken wings sparked concerns online. But experts aren’t worried.
Fast, Less Accurate Coronavirus Tests May Ease the U.S. Backlog, Experts Say
Experts are revising their views on the best methods to detect infections, setting aside long-held standards so that the spread of the virus can be more quickly tracked and contained.
Spring School Closures Over Coronavirus Saved Lives, Study Asserts
But, experts caution, the findings highlight a period when few precautions were in place, and do not apply to current discussions about reopening schools.
Moderna Coronavirus Vaccine Test in Monkeys Shows Promise
This coronavirus vaccine developed by government researchers and Moderna enabled the animals to quickly clear the infection from their lungs.
Moderna and Pfizer Begin Late-Stage Coronavirus Vaccine Trials
The studies each aim to enroll 30,000 people and determine whether the vaccines are safe and effective.
C.D.C. Data Shows U.S. Coronavirus Infections Much Higher Than Reported
Data from antibody tests in 10 different cities and states indicate that many people with no symptoms may be spreading the virus.
Drug Giants Create Fund to Bolster Struggling Antibiotic Start-Ups
New medicines are desperately needed to treat a growing number of drug-resistant infections, but many companies developing the drugs are short on cash and investments.